SCHEMBL17845498

SCHEMBL17845498

O=[N+]([O-])c1ccc(F)cc1NCCF

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KAT2B Q92831 5/20 0.50
MAPT P10636 5/20 0.47
HTR6 P50406 2/20 0.46
PKM P14618 1/20 0.45
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 2/20 0.43
SIRT5 Q9NXA8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30532042 1.00 ATM (0.51) ATMTDP1KAT2BMAPTHTR6
SCHEMBL3515437 0.86 HCAR3 (0.52) ATMTDP1KAT2BMAPTHTR6
SCHEMBL8200406 0.86 ALDH1A1 (0.55) ATMTDP1KAT2BMAPTHTR6
SCHEMBL1283854 0.83 MAPT (0.54) ATMTDP1KAT2BMAPTPKM
SCHEMBL17378355 0.83 KAT2B (0.49) KAT2BMAPTHTR6PKMGLA
SCHEMBL31481963 0.82 MAPT (0.57) ATMTDP1KAT2BMAPTHTR6
SCHEMBL3512219 0.82 MAPT (0.57) ATMTDP1KAT2BMAPTHTR6
SCHEMBL8203750 0.82 GSTM2 (0.54) ATMTDP1KAT2BMAPTALDH1A1
SCHEMBL31121972 0.82 LMNA (0.68) ATMTDP1KAT2BMAPTHTR6
SCHEMBL17845647 0.82 LMNA (0.68) ATMTDP1KAT2BMAPTHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
CN-112979631-A PARG inhibiting compounds 癌症研究科技有限公司 2021-06-18 CN disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 US disclosed
CN-107295799-B PARG inhibiting compounds 癌症研究科技有限公司 2021-03-16 CN disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 EP disclosed
CN-107295799-A Parg inhibiting compounds 癌症研究科技有限公司 2017-10-24 CN disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 ATM 2394/4885TDP1 233/4885KAT2B 2455/4885
US-20180194738-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ATM 2338/4885TDP1 223/4885KAT2B 2690/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 ATM 2338/4885TDP1 223/4885KAT2B 2690/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 ATM 2394/4885TDP1 233/4885KAT2B 2455/4885
US-20200165208-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ATM 2338/4885TDP1 223/4885KAT2B 2690/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ATM 2338/4885TDP1 223/4885KAT2B 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.